ANIX - Anixa Biosciences, Inc.
| Previous Close | 4.0000 |
| Open | 4.0500 |
| Bid | 3.9000 x 900 |
| Ask | 4.2500 x 2200 |
| Day's Range | 4.0500 - 4.2500 |
| 52 Week Range | 3.1000 - 6.8600 |
| Volume | 15,560 |
| Avg. Volume | 72,049 |
| Market Cap | 84.808M |
| Beta (3Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9580 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.25 |
- PR Newswire
Anixa Biosciences Announces VA North Texas Health Care System to Join Cchek™ Prostate Cancer Study
SAN JOSE, Calif. , July 29, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that the ...
- PR Newswire
Anixa Biosciences Announces Additional Patent Issued on Cancer Detection Technology
SAN JOSE, Calif. , July 24, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that the ...
- Simply Wall St.
Have Insiders Been Buying Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- PR Newswire
Anixa Biosciences Announces U.S. Department of Veterans Affairs VA Maryland Health Care System Joins Cchek™ Prostate Cancer Study
SAN JOSE, Calif. , July 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that it ...
- Benzinga
Anixa Bioscience's Deal With Cleveland Clinic Sends Shares Higher
Anixa Biosciences Inc (NASDAQ: ANIX) shares were trading higher Wednesday after the company announced a licensing agreement with the Cleveland Clinic for breast cancer vaccine technology. Cleveland Clinic researcher Dr. Vincent Tuohy said in a statement that he has identified a specific protein that is "retired" from service after a woman has given birth, but reappears in many forms of breast cancer, especially TNBC. Tuohy and Cleveland Clinic were awarded a $6.2-million grant from the Department of Defense in November 2017 to provide funding for the completion of pre-clinical studies as well as the completion of two Phase 1 clinical studies to test the vaccine in patients.
- PR Newswire
Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technology
Cleveland Clinic researcher Dr. Vincent Tuohy has been developing a method to vaccinate women against contracting breast cancer, focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Dr. Tuohy has identified a specific protein that is "retired" from service after a woman has given birth, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein, completely prevents breast cancer in mice. Anixa Biosciences will work with Dr. Tuohy and a team at Cleveland Clinic to advance this vaccine to clinical trials in humans to verify the animal studies that demonstrated prevention of breast cancer.
- PR Newswire
Anixa Biosciences Highlights Recent Publication in The Journal of Experimental Medicine on Myeloid Derived Suppressor Cells
The Journal of Experimental Medicine (JEM) is a peer-reviewed journal published by Rockefeller University Press dedicated to publishing outstanding and enduring studies in medical biology. The study identified monocytic precursors that are capable of differentiating into polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). MDSCs are a heterogeneous myeloid population that become pathologically activated in cancer patients and suppress antitumor immune response in the body. They are associated with poor prognosis and resistance to certain therapies and they are the primary subject of Anixa's Cchek™ early cancer detection platform. "Our collaboration with Anixa has been quite helpful in our continued work and commitment to understand the behavior of MDSCs, which play a major role in enabling tumors to evade and escape the immune system," said senior author Dmitry I. Gabrilovich, M.D., Ph.D., Christopher M. David Professor and program leader of the Immunology, Microenvironment and Metastasis Program at Wistar.
- PR Newswire
Anixa Biosciences to Present at the CYTO 2019 - 34th Congress of the International Society for Advancement of Cytometry
SAN JOSE, Calif. , May 29, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will ...
- Simply Wall St.
What Type Of Shareholder Owns Anixa Biosciences, Inc.'s (NASDAQ:ANIX)?
Every investor in Anixa Biosciences, Inc. (NASDAQ:ANIX) should be aware of the most powerful shareholder groups. Large...
- PR Newswire
Anixa Biosciences to Present at the Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum
SAN JOSE, Calif. , May 21, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that it will ...
- PR Newswire
Anixa Biosciences Announces Completion of Cchek™ Analytical Verification at CLIA Laboratory
Having completed this major validation milestone, ResearchDx, a CLIA-certified laboratory, is now processing the clinical trial samples received from Anixa's study collaborators and incorporating the resulting data into the Anixa Artificial Intelligence Training Dataset. This signals the start of the Database Generation phase of the ResearchDx clinical validation of Anixa's Cchek™ PCC test.
- PR Newswire
Anixa Biosciences to Present at B. Riley FBR Institutional Investor Conference
Anixa's presentation will be live webcast at 8:30 a.m. PDT/11:30 a.m. EDT on May 23, 2019. Please register at www.wsw.com/webcast/brileyfbr3/anix to view the live webcast. A recording of the presentation will be available on Anixa's website after the conclusion of the conference. The recording will be available for 90 days.
- PR Newswire
US Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology
SAN JOSE, Calif., April 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No. 10,259,855. This is the first patent covering Anixa's CAR-T cancer treatment technology. The patent is titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt. Dr. Conejo-Garcia is the Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Perales-Puchalt is a Senior Postdoctoral Fellow in The Wistar Institute's Vaccine & Immunotherapy Center. The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.
- PR Newswire
Anixa Biosciences Extends and Expands its Collaboration with New Jersey Urology
SAN JOSE, Calif., April 11, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it has extended and expanded its collaboration with New Jersey Urology, LLC ("NJU"). Pursuant to the extension, NJU will continue to provide patient samples for Anixa's ongoing Cchek™ early cancer detection study. Further, the collaboration has been expanded to include support of clinical validation of Anixa's Cchek™ Prostate Cancer Confirmation test with Anixa's commercialization partner, ResearchDx.
- PR Newswire
Anixa Biosciences Presents Cchek™ Prostate Cancer Detection Data at AACR Annual Meeting
SAN JOSE, Calif., April 3, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study on prostate cancer detection, utilizing Cchek™, its artificial intelligence (AI) driven cancer detection technology, at the 2019 annual meeting of the American Association of Cancer Research (AACR). The meeting was held March 29–April 3, 2019 and was attended by world leading experts across the field of cancer research. Anixa's presentation is available on the Company's website, at: www.anixa.com/cchek/recent-data.
- PR Newswire
Anixa Biosciences CEO to Present at the New York Academy of Sciences Symposium on Cancer Immunotherapy
SAN JOSE, Calif., March 27, 2019 /PRNewswire/ -- Dr. Amit Kumar, CEO of Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, will participate in a panel presentation discussing the latest science in immunotherapy at a two day symposium titled, "Frontiers in Cancer Immunotherapy," hosted by the New York Academy of Sciences on May 14–15, 2019. The panel presentation, "Will CAR-T cell Therapies, Bispecific Antibodies or TILs be more Beneficial for Solid Tumors?" will focus on a discussion about immunotherapy's potential for addressing solid tumors. Additional panel participants include Renier Brentjens, MD, PhD, Memorial Sloan Kettering Cancer Center, and Maria Fardis, PhD, MBA, Iovance Biotherapeutics. Other speakers at the conference include James Allison, PhD, MD Anderson Cancer Center, Philip Greenburg, MD, Fred Hutchison Cancer Center and Lisa Butterfield, PhD, The Parker Institute for Cancer Immunotherapy.
- PR Newswire
U.S. Department of Veterans Affairs and McGuire Research Institute Join Anixa Biosciences Cchek™ Prostate Cancer Study
SAN JOSE, Calif. , March 25, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the Hunter ...
- PR Newswire
Anixa Biosciences Announces Notice of Allowance for Additional Cancer Detection Technology Patent
SAN JOSE, Calif. , March 14, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United ...
- Simply Wall St.
Does Anixa Biosciences, Inc. (NASDAQ:ANIX) Have A Volatile Share Price?
If you're interested in Anixa Biosciences, Inc. (NASDAQ:ANIX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
- PR Newswire
Anixa Biosciences to Present Cchek™ Technology and Data at the Molecular Medicine Tri-Conference
SAN JOSE, Calif., March 4, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present its Cchek™ artificial intelligence (AI) based liquid biopsy for the early detection of cancer technology and its most recent data in an oral presentation at the 26th International Molecular Medicine Tri-Conference. Cchek™ utilizes flow cytometry of white blood cells and AI to identify tumor-bearing patients. Dr. Kumar, President and CEO of Anixa, will make his presentation at 12:15 pm on March 14, 2019. The symposium in which the presentation will be made is focused on early cancer detection (https://www.triconference.com/Circulating-DNA).
- PR Newswire
Anixa Biosciences to Present Latest Prostate Cancer Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting
SAN JOSE, Calif. , Feb. 28, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will ...
- PR Newswire
Anixa Biosciences Announces Partnership with ResearchDx for Launch of Cchek™ Prostate Cancer Confirmation Test
ResearchDx will begin clinical validation of Cchek™ PCC with the goal of launching the test in the third quarter of 2019. The steps necessary to launch the test include running samples to train the neural network (Anixa's artificial intelligence application for analysis), followed by analytical and clinical validation. Cchek™ PCC is designed to confirm the presence of cancer in a preliminarily diagnosed patient prior to biopsy. ResearchDx will perform the test in its CLIA laboratory according to the Anixa developed protocols and Artificial Intelligence (AI) analysis.
- PR Newswire
Anixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute and Leading Myeloid-derived Suppressor Cell Researcher Dmitry I. Gabrilovich, M.D., Ph.D.
SAN JOSE, Calif. , and PHILADELPHIA , Feb. 21, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced ...
- PR Newswire
Anixa Biosciences to Present at Moffitt Cancer Center's Business of Biotech Conference
SAN JOSE, Calif., Feb. 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that Dr. Amit Kumar, its President and CEO, will be presenting on a panel discussion at Moffitt Cancer Center's 13th Annual Business of Biotech Conference being held on February 22, 2019. The panel titled, "Navigating FDA Approvals for Cell Therapy" will focus on regulatory aspects of developing CAR-T and other cell therapies. In addition to Dr. Kumar, other participants on the panel will include executives from Atara Biotherapeutics, Inc., Intellia Therapeutics, Inc., and Iovance Biotherapeutics, Inc.
- Simply Wall St.
What Are Analysts Saying About Anixa Biosciences, Inc.’s (NASDAQ:ANIX) Earnings Trajectory?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anixa Biosciences, Inc.'s (NASDAQ:ANIX) latest earnings announcement Read More...
